ELV — Elevance Health Inc.

Q2 2026 adjusted EPS of $7.45 beat expectations and management raised full-year 2026 adjusted EPS guidance to at least $27.00. Wall Street remains Buy-rated with a consensus target near $444, and FMP's rating breakdown shows 27 buys, 11 holds, and 0 sells. The move is constructive but not overbought, with RSI near 53.

Revenue growth has decelerated sharply over the past year: YoY growth went from +14.8% in Q1 2025 and +14.1% in Q2 2025 to just +2.6% in Q1 2026 and +1.4% in Q2 2026. TTM operating margin is roughly 3.5%, down from about 4.5% a year earlier, and TTM EPS has slipped from roughly $23.50 to $22.78. Q4 is consistently the weakest quarter—Q4 2025 operating income was only $0.58B versus $2.66B in Q1 2026—but the overall picture is deceleration and margin compression, not just a one-quarter blip.

Mixed on trailing GAAP, cheap on forward earnings: trailing P/E of 17.7x is roughly in line with the 5-year average of 17.2x, while P/S of 0.43x is well below the 5-year average of 0.62x. On 2026 adjusted EPS guidance of at least $27.00, the forward P/E is ~14.8x; on the 2027 target of at least 12% growth, it drops to ~13.2x. That is not expensive, but the low operating margin and government-payer exposure justify a discount to higher-quality healthcare compounders.

At $399.11, the market is pricing in meaningful skepticism about Elevance's ability to hold margins and achieve its 12% 2027 EPS growth target. If AI-driven utilization controls and Carelon growth deliver, the stock is cheaply priced relative to guided earnings. If medical costs re-accelerate or government program headwinds worsen, the low forward multiple will look deserved. This is a show-me setup: the bullish earnings trajectory is not yet confirmed by trailing results.

As of 2026-08-27, RSI(14) is 53.1, price is 1.22% above the 20-day SMA, 1.11% above the 50-day SMA, and 11.85% above the 200-day SMA. The stock is in a longer-term recovery off the $274.84 low but is consolidating below the $436.24 high. No overbought/oversold signal; entry timing is neutral until a breakout or a cleaner pullback toward the 50-day develops.

• High medical utilization and benefit expense across managed care remain the key margin headwind; AI-driven prior authorization and payment integrity are the main offsets.
• Medicare Advantage funding, Star ratings, and Medicaid redetermination attrition continue to pressure government-program revenue and margins.
• Easing Treasury yields and defensive sector rotation support income-bearing healthcare names like ELV with a 1.7% dividend yield.
• Regulatory and policy risk around PBMs, insurance mandates, and drug pricing can move the entire managed-care group.
• Commercial membership expansion, including the Wellpoint launch in Washington state, partially offsets Medicaid attrition.

• Q3 2026 earnings in mid-October: evidence that AI cost controls continue to offset medical utilization pressure.
• 2027 guidance and investor updates confirming management's stated target of at least 12% adjusted EPS growth.
• Scaling of Carelon services and potential Medicare Advantage quality rating improvements.

• Medical loss ratio deterioration from higher utilization or inadequate premium rates.
• Medicaid and Medicare reimbursement cuts, redetermination attrition, or adverse regulatory changes.
• Continued deceleration in revenue growth and further operating margin compression.
• Execution risk in the AI/Transformation Program and Carelon investments; long-term debt of $30.7B and debt-to-equity of 0.69 are manageable but not negligible.

Elevance is a high-quality managed-care franchise with a genuinely weak trailing fundamental picture: revenue growth has slowed to low single digits, TTM operating margin is only ~3.5%, and ROIC is ~6.6%. However, the stock is cheap on forward guidance and the market is not paying for management's 12% 2027 EPS growth target. This is a cautious value situation rather than a confident growth story; I would need to see Q3 margins hold before treating the pessimism as overdone.

I applied a conservative forward P/E of 14.5x—deliberately below ELV's 5-year average of 17.2x to reflect margin compression and government-payer risk—to management's 2027 EPS target of roughly $30.24 (2026 floor of $27.00 plus 12% growth), yielding $438.48. This is my own estimate, not a restatement of the $444.06 consensus target.